service and then served as a researcher in the Queen Astrid
Military Hospital (QAMH) in Brussels. He is head of the Laboratory
for Molecular and Cellular Technology (LabMCT), which harbours
the human cell and tissue banks of the QAMH, and was recently
appointed as research collaborator at the Royal Military Academy.
He is involved in several research projects, including the
development of therapeutic bacteriophage cocktails against multidrug
resistant pathogens (Pseudomonas aeruginosa, MRSA,
Acinetobacter baumannii, EHEC, mycobacteria,..). He has
published about 60 peer reviewed journal articles and book
chapters. His publications reflect his wide interests, from molecular
microbiology to ethical issues.
ALTERNATIVES TO ANTIBIOTICS
114 AMR CONTROL 2015
References
1. Fleming, A. Nobel prize Lecture, 1945
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf).
2. Allen HK, Donato J, Wang HH et al. Call of the wild: antibiotic resistance genes in natural
environments. Nat Rev Microbiol 2010;8:251-9
3. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and
responses. Nat. Med. 10(12), S122-S129 (2004)
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial
pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008)
5. European Centre for Disease Prevention and Control (ECDC) & European Medicines
Agency (EMEA). Joint technical report: the bacterial challenge: time to react (ECDCEMEA,
Stockholm, 2009)
6. Antimicrobial resistance: Global report on Surveillance. Geneva, World Health
Organization (WHO), 2014. Available from:
http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
(accessed 18/09/14).
7. Baquero F, Coque TM and Canton R. Antibiotics, complexity and evolution. ASM News,
2003, 69:547-552
8. Pirnay J-P, De Vos D, Zizi M and Heyman P. (2003). No easy way to exterminate
'superbugs' at the dawn of the third millennium. Exp. Rev. Anti-Infectiv. Ther. 1, 523-525
9. Thiel K. Old dogma, new tricks - 21st century phage therapy. Nat. Biotechnol. 22(1), 31-
36 (2004).
10. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al. Tackling
antibiotic resistance. Nat Rev Microbiol. 2011;9:894-6
11. Twort, F. W. An investigation on the nature of the ultramicroscopic viruses. Lancet, 1915,
186, 1241-1243
12. D'Hérelle F. Sur le rôle du microbe bactériophage dans la typhose aviaire. C. R. Acad. Sci.
169, 932-934 (1919)
13. Sulakvelidze, A.; Kutter, E. Bacteriophage therapy in humans. In: Bacteriophages: Biology
and Application; Kutter, E., Sulakvelidze, A., Eds.; CRC Press: Boca Raton, Florida, 2005,
pp. 381-436
14. Whiteley M, Bangera MG, Burngarner RE et al. Gene expression in Pseudomonas
aeruginosa biofilms. Nature 2001;413:860-4
15. Beloin C, Valle J, Latour-Lambert P et al. Global impact of mature biofilm lifestyle on
Escherichia coli K-12 gene expression. Mol Microbiol 2004;51:659-74
16. Comeau AM, Tetart F, Trojet SN, Prere MF and Krish HM. Phage-antibiotic synergy
(PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One
2007, e799
17. Brussow H. Phage therapy: the Escherichia coli experience. 2005 151, 2133-2140
18. Smith HW and Huggins MB. Successful treatment of experimental Escherichia coli
infections in mice using phage: its general superiority over antibiotics. J Gen. Microbiol.
1982 128, 307-318
19. Chanishvili N, Sharp R. Eliava Institute of Bacteriophage, Microbiology and Virology,
Tbilisi, Georgia. A literature review of the practical application of bacteriophage research.
Tbilisi: Eliava Foundation; 2009
20. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W,
et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs.
2009;10:766-74
21. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S and Abedon ST. Phage
therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 2010
11, 69-86
22. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, et al.
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use
in human clinical trials. PLoS One. 2009;4:e4944.
23. Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S,
Zizi M, and Pirnay J-P. 2014. Experimental phage therapy: Difficult first steps.
International Journal of Burns and Trauma. Accepted 140916
24. Phage Therapy, Current Research and Applications. 2014. Edited by Boryzsowski J,
Miedzybrodski R and Gorski A. Caister Academic press, 2014
25. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS and Sulakvelidze A.
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J.
Wound Care 2009 18, 237-243
26. Khawaldeh A, Morales S, Dillon,B, Alavidze, Z, Ginn AN, Thomas L, Chapman SJ,
Dublanchet A, Smithyman A and Iredell JR. Bacteriophage therapy for refractory
Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 2011 60, 1697-1700
27. Bergh O, Borsheim, KY, Bratbak G and Heldal M. High abundance of viruses found in
aquatic environments. Nature 1989 340, 476-468
28. Fuhrman JA. (1999). Marine viruses and their biogeochemical and ecological effects.
Nature 399, 541-548
27. Hendrix RW. Bacteriophages: evolution of the majority. Theor. Popul. Biol. 61(4), 471-
480 (2002)
29. Bamford DH. (2003). Do viruses form lineages across different domains of life? Res.
Microbiol. 154, 231-236.
30. Shanks N and Pyles RA. (2007). Evolution and medicine: the long reach of 'Dr. Darwin'.
Philos. Ethics Humanit. Med. 2, 4
31. Raoult D and Forterre P. (2008). Redefining viruses: lessons from the mimivirus. Nat. Rev.
Microbiol. 6, 315-319
32. Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliaeno J, Stotland A, Wolkowicz R.,
Cutting AS, Doran KS, et al. (2013). Bacteriophage adhering to mucus provide a non-hostderived
immunity. Proc. Natl. Acad. Sci. USA. 110, 10771-10776
33. Sulakvelidze A. The challenges of bacteriophage therapy. Eur. Ind. Pharm. 10, 14-18
(2011)
34. Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic
from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 70 (1),
204-210 (2002)
35. Brüttin A and Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a
safety test of phage therapy. Antimicrob. Agents Chemother. 49(7), 2874-2878 (2005)
36. Blaser M. Missing Microbes: How the overuse of antibiotics is fuelling our modern
Plagues, 2014, Henry Holt and Company, New York
37. Pirnay J-P, De Vos D, Verbeken G, Merabishvili M., Chanishvili N, Vaneechoutte M, Zizi
M, Laire G, Lavigne R, Huys I, et al. (2010). The Phage therapy paradigm: pret-a-porter or
sur-mesure? Pharm. Res.28, 934-937
38. Pirnay J-P, Verbeken G, Rose T, Jennes S, Zizi M, Huys I, Lavigne R, Merabishvili M,
Vaneechoutte M, Buckling A., and De Vos D. (2012). Introducing yesterday's phage
therapy in today's medicine. Future Virol. 7, 379-390
39. Merabishvili M, De Vos D, Verbeken G, Kropinski AM, Vandenheuvel D, Lavigne R, et al.
Selection and characterization of a candidate therapeutic bacteriophage that lyses the
Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One.
2012;7:e52709
40. De J Sosa A, Byarugaba DK, Amabile-Cuevas CF, Hsueh P-R, Kariuki S and Okeke IN.
(eds). Antibiotic resistance in developing countries. Springer, 2010. (DOI 10.1007/978-0387-89370-9)
41. Faruque SM, Naser IB, Islam MJ et al. Seasonal epidemics of cholera inversely correlate
with the prevalence of environmental cholera phages. Proc. Natl Acad. Sci. USA 102(5),
1702-1707 (2005)
42. Faruque SM, Islam MJ, Ahmad QS et al. Self-limiting nature of seasonal cholera
epidemics: role of host-mediated amplification of phage. Proc. Natl Acad. Sci. USA 102(17),
6119-6124 (2005)
43. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M and Pirnay J-P. (2007).
European regulatory conundrum of phage therapy. Future Microbiol. 2, 485-491.
44. Verbeken G, Pirnay JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M, Huys I.
Optimizing the European regulatory framework for sustainable bacteriophage therapy in
human medicine. Arch Immunol Ther Exp (Warsz). 2012;60:161-72.